Demystifying the contemporary role of 12-month dual antiplatelet therapy after acute coronary syndrome
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) has been the only class I recommendation on DAPT in American and …
syndrome (ACS) has been the only class I recommendation on DAPT in American and …
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets
F D'Ascenzo, O De Filippo, G Gallone, G Mittone… - The Lancet, 2021 - thelancet.com
Background The accuracy of current prediction tools for ischaemic and bleeding events after
an acute coronary syndrome (ACS) remains insufficient for individualised patient …
an acute coronary syndrome (ACS) remains insufficient for individualised patient …
Antithrombotic therapy in elderly patients with acute coronary syndromes
C Bonanad, F Esteve-Claramunt, S García-Blas… - Journal of Clinical …, 2022 - mdpi.com
The treatment of acute coronary syndrome (ACS) in elderly patients continues to be a
challenge because of the characteS. GB ristics of this population and the lack of data and …
challenge because of the characteS. GB ristics of this population and the lack of data and …
Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment
X Zhang, X Zhang, F Tong, Y Cai, Y Zhang, H Song… - Elife, 2022 - elifesciences.org
Background: Ticagrelor is a first-line drug for the treatment of acute ST elevation myocardial
infarction (STEMI). However, approximately 20% STEMI patients taking ticagrelor exhibited …
infarction (STEMI). However, approximately 20% STEMI patients taking ticagrelor exhibited …
Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions
This review is a summary of the European Society of Cardiology (ESC) guidelines focused
on dual antiplatelet therapy in patients after percutaneous coronary interventions (PCI) …
on dual antiplatelet therapy in patients after percutaneous coronary interventions (PCI) …
Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta‐Analysis and Systematic Review
G Saint Croix, SC Lacy, A Gazzhal… - Journal of …, 2022 - Wiley Online Library
Objectives. This systematic review and meta‐analysis evaluates the safety and efficacy of
dual antiplatelet therapy (DAPT) in elderly patients with acute coronary syndrome (ACS) …
dual antiplatelet therapy (DAPT) in elderly patients with acute coronary syndrome (ACS) …
Prognostic impacts of β-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention
RZ Chen, C Liu, P Zhou, JN Li, JY Zhou, Y Wang… - Pharmacological …, 2021 - Elsevier
Abstracts Background The use of β-blockers for acute coronary syndrome (ACS) patients
without heart failure (HF) is controversial, and lacks of evidence in the era of reperfusion and …
without heart failure (HF) is controversial, and lacks of evidence in the era of reperfusion and …
Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
Y Kim, MH Jeong, M An, K Cho, Y Hong, J Kim, Y Ahn - Plos one, 2023 - journals.plos.org
Background and objectives To compare the long-term clinical outcomes of dual antiplatelet
therapy (DAPT) with clopidogrel and DAPT with ticagrelor or prasugrel in patients with acute …
therapy (DAPT) with clopidogrel and DAPT with ticagrelor or prasugrel in patients with acute …
Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention
SH Ann, MH Strauss, GM Park, S Han, Y Yang… - International Journal of …, 2020 - Elsevier
Background The inhibitors for renin-angiotensin-aldosterone system (RAAS) have different
mechanisms of action in coronary artery disease (CAD). This study sought to compare the …
mechanisms of action in coronary artery disease (CAD). This study sought to compare the …
Impact of insulin-treated and noninsulin-treated diabetes mellitus in all-comer patients undergoing percutaneous coronary interventions with polymer-free biolimus …
M Pepe, G Sardella, GG Stefanini, N Corcione… - The American Journal of …, 2019 - Elsevier
Patients with diabetes mellitus (DM) have worse outcomes after percutaneous coronary
intervention (PCI). Recent evidences suggest a differential impact of insulin-treated and …
intervention (PCI). Recent evidences suggest a differential impact of insulin-treated and …